logo-loader
viewTRACON Pharmaceuticals

TRACON Pharmaceuticals bolsters its board with appointment of Saundra Pelletier as a director

TRACON is advancing targeted therapies for cancer and its pipeline includes Envafolimab

TRACON Pharmaceuticals -
"TRACON has a first-class management team, an efficient platform to conduct global clinical trials, and a promising drug candidate with near-term commercial potential in envafolimab,” Pelletier said

TRACON Pharmaceuticals Inc (NASDAQ:TCON) has named Saundra Pelletier, who currently heads up Evofem Biosciences Inc (NASDAQ:EVFM), as a new board director.

Pelletier is currently CEO, president and an executive director, at Evofem, which is a clinical-stage biopharmaceutical company focused on women’s sexual and reproductive health. She is leading that firm's effort to bring Phexxi, a new, non-hormonal contraceptive candidate, to women. Pelletier was named San Diego Business Journal's 2019 Businesswoman of the Year.

READ: TRACON Pharmaceuticals requests FDA meeting to discuss pivotal study design for Envafolimab to treat sarcoma

"We are very pleased to welcome Saundra to the TRACON Board," Dr Charles Theuer, the president and CEO of San Diego-based TRACON said in a statement.

"Her strong track record of successful strategic, operational and financial management, combined with her vast commercial experience will be invaluable to TRACON as we execute on our plan to complete clinical development and commercialize envafolimab in the United States by 2023."

TRACON is advancing targeted therapies for cancer and its clinical-stage pipeline includes Envafolimab, a subcutaneous PD-L1 single-domain antibody being developed to treat sarcoma.

"TRACON has a first-class management team, an efficient platform to conduct global clinical trials, and a promising drug candidate with near-term commercial potential in envafolimab,” Pelletier commented. 

"As a cancer survivor and woman’s health advocate, I am thrilled to support TRACON’s mission and help advance its broad oncology pipeline, which has the potential to address significant unmet needs across multiple tumor types.”

Shares nudged up 3.6% in New York to US$1.15 each.

Contact the author at [email protected]

Quick facts: TRACON Pharmaceuticals

Price: 2.3 USD

NASDAQ:TCON
Market: NASDAQ
Market Cap: $12.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

TRACON Pharmaceuticals looks forward to positive Phase 2 cancer trial data...

TRACON Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer tells Proactive its corporate partners will present positive data from a Phase 2 cancer trial of the drug envafolimab at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. Theuer says the trial enrolled...

2 weeks, 2 days ago

2 min read